Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer

Human epidermal growth factor receptor 2–targeted (HER2-targeted) therapy is the mainstay of treatment for HER2(+) breast cancer. However, the proteolytic cleavage of HER2, or HER2 shedding, induces the release of the target epitope at the ectodomain (ECD) and the generation of a constitutively acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Muwen, Li, Kong, Lingzhi, Huang, Shumei, He, Lixin, Liu, Pian, Mo, Shuang, Lu, Xiuqing, Lin, Xi, Xiao, Yunyun, Shi, Dongni, Huang, Xinjian, Chen, Boyu, Chen, Xiangfu, Ouyang, Ying, Lin, Chuyong, Song, Libing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348774/
https://www.ncbi.nlm.nih.gov/pubmed/37463446
http://dx.doi.org/10.1172/JCI164428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348774/
https://www.ncbi.nlm.nih.gov/pubmed/37463446
http://dx.doi.org/10.1172/JCI164428

Ejemplares similares